In part 1 of this eHIV Review Special Edition (still available at eHIVreview.org), eHIV Review Program Director Justin Alves, Nurse Educator at Boston Medical Center, reviewed the recent evidence describing some of the barriers to care experienced by marg

Non-nucleoside reverse transcriptase inhibitors (NNRTIs). Rilpivirine, in combination with cabotegravir, provides a long-acting injectable option for both treatment and PrEP. But what risk factors have been associated with virologic failure? Doravirine ap

Hosted on Acast. See acast.com/privacy for more information.

Stigma. What is it, and where does it come from? How do LGBTQ+ individuals, particularly those with HIV, experience it? How does stigma affect their mental health? What effect does it have on their engagement in HIV care? What do health care providers nee

Treatment-experienced patients with RAMs resistance-associated mutations remain a difficult management challenge. Every case of HIV drug resistance requires a therapeutic regimen individualized for each patients ART history. How will new and in-devel

Most people living with HIV gain weight when initiating ART. For some, the weight gain signifies a return to health; for others, the additional weight can be clinically significant and may be strongly associated with an increased risk of metabolic abnor

Are PLWH at higher risk for increased mortality from COVID-19 infection? How important is it for PWLH to get vaccinated and boosted? Is breakthrough COVID-19 infection more likely to occur among PLWH? What about “long COVID” (PASC)?Join Clinical Research

Long-acting injectable antiretroviral therapy is expected to improve adherence, reduce patient burden, and lower community viral load. But for which patients is it suitable? Can it be used as pre-exposure prophylaxis? How does the promise of long-acting A

Twenty percent of new HIV diagnoses occur among adolescents and young adults. Theyre a population underserved by HIV prevention resources, with lower retention in HIV care. Their awareness and uptake of PrEP has been and remains low. What can their

Rapid ART initiating ART as soon as possible after an HIV diagnosis: How effective is it at bringing people with newly diagnosed HIV into lasting care? When and how should it be initiated? Are there particular populations where attempting rapid ART shou